I took ImClone to task here for putting a Hollywood studio executive on its Board of Directors. The post caused me to be frozen out of communication with the company--calls were not returned, emails did not get a reply.
We've since mended fences and it looks like IMCL may have gotten a message. Here's part of its press release issued late yesterdayannouncing that Dr. Thomas Deuel is coming onto the Board. Check out how much copy is spent touting his medical bona fides:
"Tom Deuel has a strong scientific background in oncology and, as a former member of our scientific advisory board, is extremely knowledgeable about Erbitux(R) and ImClone's extensive pipeline," stated Alexander J. Denner, Ph.D., Chairman of ImClone Systems' Executive Committee. "We welcome him to the Board and look forward to the important contributions he will make."
Since February, 2002, Dr. Deuel has served as a Professor of Molecular and Experimental Medicine and Cell Biology, Director of the Division of Molecular Oncology, Department of Molecular and Experimental Medicine, and Director of the Vascular Biology Affinity Group at The Scripps Research Institute. Prior to joining The Scripps Research Institute, Dr. Deuel served as a Professor of Medicine at Harvard Medical School. He is currently a Professor Emeritus at Harvard Medical School. In addition, from 1996 to 2002, Dr. Deuel served as a Director, Division of Growth Regulation at Beth Israel Hospital, Boston, Massachusetts and, prior to that, was a Professor of Medicine and Biochemistry and the head of Oncology Services at the Washington University School of Medicine, St. Louis, Missouri.
Dr. Deuel is a member of the Institute of Medicine at the National Academy of Sciences. Dr. Deuel has served and continues to serve on numerous scientific advisory boards for various companies, including the Company's scientific advisory board during its existence. In addition, Dr. Deuel has earned many professional honors and awards. Dr. Deuel holds an M.D. from Columbia University and an A.B. from Princeton University.
Carl Icahnis the Chairman of ImClone. The company still has no CEO. Maybe we'll get an update on the search when IMCL reports earnings soon.
Questions? Comments? Pharma@cnbc.com